Marc Goodman
Stock Analyst at Leerink Partners
(2.95)
# 1,620
Out of 5,048 analysts
94
Total ratings
58.11%
Success rate
28.8%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVDL Avadel Pharmaceuticals | Downgrades: Market Perform | $19 | $18.92 | -2.22% | 3 | Oct 23, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $16.17 | +110.27% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $14.85 | +236.70% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $13.60 | -26.47% | 5 | May 7, 2025 | |
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $135.75 | +10.50% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $2.20 | -54.55% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $27.93 | +14.57% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $112.40 | -77.76% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $15.36 | +225.52% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $6.39 | +212.99% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $141.96 | -18.99% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $151.44 | +104.70% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $41.12 | +11.87% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $22.37 | -6.12% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $138.38 | +51.76% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.18 | +214.47% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $30.17 | -10.51% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.23 | +186.81% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $517.43 | -47.82% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $211.96 | -54.71% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $46.02 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $82.49 | -18.78% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $20.53 | +377.35% | 7 | Oct 5, 2017 |
Avadel Pharmaceuticals
Oct 23, 2025
Downgrades: Market Perform
Price Target: $19
Current: $18.92
Upside: -2.22%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $16.17
Upside: +110.27%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $14.85
Upside: +236.70%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $13.60
Upside: -26.47%
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $135.75
Upside: +10.50%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $2.20
Upside: -54.55%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $27.93
Upside: +14.57%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $112.40
Upside: -77.76%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $15.36
Upside: +225.52%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $6.39
Upside: +212.99%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $141.96
Upside: -18.99%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $151.44
Upside: +104.70%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $41.12
Upside: +11.87%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $22.37
Upside: -6.12%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $138.38
Upside: +51.76%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.18
Upside: +214.47%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $30.17
Upside: -10.51%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.23
Upside: +186.81%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $517.43
Upside: -47.82%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $211.96
Upside: -54.71%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $46.02
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $82.49
Upside: -18.78%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $20.53
Upside: +377.35%